Ryvu Therapeutics S.A. (WSE: RVU)

Market Cap	683.20M
Revenue (ttm)	91.18M
Net Income (ttm)	-104.14M
Shares Out	23.12M
EPS (ttm)	-4.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,405
Average Volume	14,167
Open	30.20
Previous Close	30.05
Day's Range	29.00 - 30.40
52-Week Range	29.00 - 61.00
Beta	0.65
RSI	20.76
Earnings Date	Mar 14, 2025

About Ryvu Therapeutics

Ryvu Therapeutics S.A., a biotechnology company, engages in developing of small molecule therapies for treatment in oncology in Poland, rest of the European Union, and internationally. Its lead candidate, RVU120, is a CDK8 and CDK19 kinase inhibitor in Phase 2 clinical trial with potential to treat hematological malignancies, solid tumors, acute myeloid leukemia, myelodysplastic syndrome, and myelofibrosis. The company also develops SEL24/MEN1703, a dual PIM and FLT3 kinase inhibitor licensed to the Menarini Group that is in study start-up for ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 270
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: RVU

Financial Performance

In 2023, Ryvu Therapeutics's revenue was 67.30 million, a decrease of -1.67% compared to the previous year's 68.44 million. Losses were -92.11 million, 9.94% more than in 2022.